- Home
- Publications
- Publication Search
- Publication Details
Title
New therapies for neuromyelitis optica spectrum disorder
Authors
Keywords
-
Journal
LANCET NEUROLOGY
Volume 20, Issue 1, Pages 60-67
Publisher
Elsevier BV
Online
2020-11-11
DOI
10.1016/s1474-4422(20)30392-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
- (2020) Anthony Traboulsee et al. LANCET NEUROLOGY
- Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial
- (2020) Chao Zhang et al. LANCET NEUROLOGY
- Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
- (2020) Masayuki Tahara et al. LANCET NEUROLOGY
- Satralizumab: First Approval
- (2020) Young-A Heo DRUGS
- Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
- (2019) Kioa Lente Wijnsma et al. CLINICAL PHARMACOKINETICS
- Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
- (2019) Fulin Gao et al. BMC Neurology
- Expanding the spectrum of MOG antibody disease
- (2019) Michael Levy Multiple Sclerosis Journal
- Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
- (2019) Sean J. Pittock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
- (2019) Bruce A C Cree et al. LANCET
- Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin‐4 Antibody Diseases
- (2019) Pierre Durozard et al. ANNALS OF NEUROLOGY
- Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
- (2019) Takashi Yamamura et al. NEW ENGLAND JOURNAL OF MEDICINE
- Investigational drugs in development to prevent neuromyelitis optica relapses
- (2018) Friedemann Paul et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica
- (2018) Lukmanee Tradtrantip et al. NEUROPHARMACOLOGY
- MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder
- (2018) Ram Narayan et al. Multiple Sclerosis and Related Disorders
- Racial differences in neuromyelitis optica spectrum disorder
- (2018) Su-Hyun Kim et al. NEUROLOGY
- Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial
- (2017) Zahra Nikoo et al. JOURNAL OF NEUROLOGY
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
- (2017) James F Howard et al. LANCET NEUROLOGY
- Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
- (2017) Mark A Agius et al. Multiple Sclerosis Journal
- Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
- (2017) Mark A Agius et al. Multiple Sclerosis Journal
- Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders
- (2016) Valentina Damato et al. JAMA Neurology
- Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase
- (2015) P. O. Barros et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Placebo-controlled study in neuromyelitis optica—Ethical and design considerations
- (2015) Bruce AC Cree et al. Multiple Sclerosis Journal
- Challenges and opportunities in designing clinical trials for neuromyelitis optica
- (2015) B. G. Weinshenker et al. NEUROLOGY
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
- (2015) Dean M. Wingerchuk et al. NEUROLOGY
- Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder
- (2015) Marius Ringelstein et al. JAMA Neurology
- Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica
- (2015) Su-Hyun Kim et al. JAMA Neurology
- Placebo-controlled study in neuromyelitis optica—Ethical and design considerations
- (2015) Bruce AC Cree et al. Multiple Sclerosis Journal
- The ethics of placebo controlled clinical trials in NMO – A balance of risks
- (2015) Michael Levy Multiple Sclerosis and Related Disorders
- Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study
- (2014) M. Araki et al. NEUROLOGY
- Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study
- (2013) Sean J Pittock et al. LANCET NEUROLOGY
- Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis
- (2013) Takuya Matsushita et al. PLoS One
- Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy
- (2013) Ilya Ayzenberg et al. JAMA Neurology
- Epidemiology of Neuromyelitis Optica in the United States
- (2012) Maureen A. Mealy et al. ARCHIVES OF NEUROLOGY
- Treatment of neuromyelitis optica: Review and recommendations
- (2012) Dorlan J. Kimbrough et al. Multiple Sclerosis and Related Disorders
- Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
- (2011) Norio Chihara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IL-6: Regulator of Treg/Th17 balance
- (2010) Akihiro Kimura et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6
- (2010) Akiyuki Uzawa et al. Multiple Sclerosis Journal
- Prediction of Neuromyelitis Optica Attack Severity by Quantitation of Complement-Mediated Injury to Aquaporin-4–Expressing Cells
- (2009) Shannon R. Hinson et al. ARCHIVES OF NEUROLOGY
- Treatment of Neuromyelitis Optica With Rituximab
- (2008) ARCHIVES OF NEUROLOGY
- The effects of IL-6 on CD4 T cell responses
- (2008) Oliver Dienz et al. CLINICAL IMMUNOLOGY
- NMO-IgG predicts the outcome of recurrent optic neuritis
- (2008) M. Matiello et al. NEUROLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started